Business Context and Reporting Period
This Form 8-K Current Report was filed by Zentalis Pharmaceuticals, Inc. on May 25, 2022. The filing primarily addresses Item 5.02 regarding the appointment of a new President and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics for the reporting period. The only specific financial data disclosed relates to executive compensation and a prior milestone payment:
- Executive Base Salary: $560,000 annually for the new President.
- Executive Bonus Target: 50% of annual base salary.
- Equity Grants: 333,218 stock options and 111,072 restricted stock units (RSUs).
- Prior Milestone Payment: $10.0 million paid to Recurium IP Holdings, LLC in the year ended December 31, 2021.
Material Changes
The primary material change reported is the leadership transition effective May 30, 2022:
- Appointment: Cam S. Gallagher, a current Executive Director and Board member, was appointed as President.
- Departure: Kimberly Blackwell is succeeding in the role of President.
- Compensation Structure: Mr. Gallagher entered into an amended and restated employment agreement with Zeno Management, Inc., establishing new salary, bonus, and equity terms.
Outlook, Risks, and Contingencies
Management Commentary and Compensation Terms:
- Severance Provisions: In the event of termination without cause or resignation for good reason, Mr. Gallagher is entitled to 12 months of base salary, a prorated target bonus, and 18 months of COBRA premiums. If termination occurs within 18 months of a change in control, he receives a full target bonus instead of the prorated amount, and all stock awards vest immediately.
- Related Party Transaction: Mr. Gallagher serves as the managing member of Recurium IP Holdings, LLC, the holder of the exclusive worldwide license to the Company's core intellectual property. The Company paid $10.0 million in milestone fees to Recurium IP in 2021.
Risks: The filing highlights the Company's reliance on intellectual property licensed from a related party entity managed by the new President.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price for the 333,218 stock options granted to Mr. Gallagher.
- Review the full text of the Amended and Restated Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason."
- Assess the financial impact of the $10.0 million milestone payment to Recurium IP and any future milestone obligations under the license agreement.
- Confirm the status of Kimberly Blackwell's departure and any associated severance or transition arrangements not detailed in this summary.